Candel Therapeutics (CADL) announced the appointment of Maha Radhakrishnan, M.D., to the Company’s Board of Directors effective June 4, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics’ CAN-2409: Promising Phase 3 Results and Buy Rating for Prostate Cancer Treatment
- Buy Recommendation for Candel Therapeutics: Promising Data on CAN-2409 Treatment for Prostate Cancer
- Candel Therapeutics to hold a conference call
- Candel Therapeutics Receives FDA RMAT Designation for CAN-2409
- Candel Therapeutics receives FDA RMAT designation to CAN-2409